Fabio Ciceri Selected Research

Cyclophosphamide (Cytoxan)

10/2022	Comparison of Outcomes after Unrelated Double-Unit Cord Blood and Haploidentical Peripheral Blood Stem Cell Transplantation in Adults with Acute Myelogenous Leukemia: A Study on Behalf of Eurocord and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
2/2022	Addition of a Single Low Dose of Anti T-Lymphocyte Globulin to Post-Transplant Cyclophosphamide after Allogeneic Hematopoietic Stem Cell Transplant: A Pilot Study.
1/2022	Impact of donor kinship on non-T-cell depleted haploidentical stem cell transplantation with post transplantation cyclophosphamide for acute leukemia: From the ALWP of the EBMT.
1/2022	Post-transplant cyclophosphamide in one-antigen mismatched unrelated donor transplantation versus haploidentical transplantation in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the EBMT.
1/2022	Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia.
1/2022	Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide versus Cyclosporine A and Methotrexate in Matched Sibling Donor Transplantation.
1/2022	The association of graft-versus-leukemia effect and graft-versus host disease in haploidentical transplantation with post-transplant cyclophosphamide for AML.
12/2021	Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
1/2021	Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT.
1/2021	Allogeneic bone marrow transplantation in HIV people with hematological malignancies: Post-transplant cyclophosphamide to overcome the HLA-matching barrier.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Fabio Ciceri Research Topics

Disease

85	Leukemia 10/2022 - 11/2002
64	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 10/2022 - 01/2006
55	Graft vs Host Disease (Graft-Versus-Host Disease) 10/2022 - 01/2002
52	COVID-19 06/2022 - 01/2020
50	Neoplasms (Cancer) 01/2022 - 01/2002
24	Hematologic Neoplasms (Hematological Malignancy) 01/2022 - 01/2002
23	Infections 02/2022 - 11/2004
22	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2022 - 04/2009
13	Pneumonia (Pneumonitis) 02/2022 - 01/2020
12	Lymphoma (Lymphomas) 12/2021 - 09/2004
12	Multiple Myeloma 12/2021 - 12/2002
9	Philadelphia Chromosome 01/2021 - 08/2010
8	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2022 - 07/2009
7	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 11/2020 - 07/2008
6	Inflammation (Inflammations) 10/2021 - 07/2014
6	Hodgkin Disease (Hodgkin's Disease) 11/2020 - 03/2008
5	Fever (Fevers) 01/2022 - 07/2014
5	Severe combined immunodeficiency due to adenosine deaminase deficiency 01/2021 - 01/2009
5	Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome) 01/2021 - 01/2009
5	Residual Neoplasm 12/2020 - 04/2009
5	beta-Thalassemia (Cooley's Anemia) 06/2011 - 09/2007
4	Pathologic Complete Response 10/2022 - 01/2002
4	Respiratory Insufficiency (Respiratory Failure) 02/2022 - 01/2021
4	Cytokine Release Syndrome 11/2021 - 01/2018
4	Hematologic Diseases (Blood Diseases) 01/2021 - 03/2010
4	Hypertension (High Blood Pressure) 09/2020 - 01/2009
4	B-Cell Lymphoma (Lymphoma, B Cell) 01/2020 - 09/2004
4	Disease Progression 01/2020 - 06/2005
4	Metachromatic Leukodystrophy (Sulfatide Lipidosis) 12/2019 - 08/2013
4	Thalassemia 01/2019 - 05/2010
4	Autoimmune Diseases (Autoimmune Disease) 01/2019 - 05/2011
3	Hepatic Veno-Occlusive Disease (Disease, Hepatic Veno-Occlusive) 01/2022 - 11/2009
3	Hypogonadism (Hypergonadotropic Hypogonadism) 01/2022 - 01/2021
3	Anemia 10/2021 - 04/2011
3	Primary Myelofibrosis (Myelosclerosis) 01/2021 - 09/2016
3	Multiple Sclerosis 01/2021 - 06/2005
3	Cardiotoxicity 05/2020 - 01/2018
3	Bronchiolitis Obliterans Syndrome 02/2020 - 01/2015

Drug/Important Bio-Agent (IBA)

41	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2022 - 01/2002
20	AntigensIBA 01/2022 - 11/2004
15	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2006
11	HLA Antigens (Human Leukocyte Antigens)IBA 01/2022 - 11/2008
10	CytokinesIBA 01/2022 - 11/2004
9	C-Reactive ProteinIBA 01/2022 - 11/2005
9	Antilymphocyte Serum (Anti-Thymocyte Globulin)IBA 01/2021 - 01/2017
9	Rituximab (Mabthera)FDA Link 11/2020 - 07/2008
8	treosulfanIBA 01/2022 - 08/2015
8	Tyrosine Kinase InhibitorsIBA 01/2022 - 10/2016
8	Methotrexate (Mexate)FDA LinkGeneric 01/2022 - 12/2009
8	Interleukin-6 (Interleukin 6)IBA 04/2021 - 01/2018
8	Pharmaceutical PreparationsIBA 11/2020 - 05/2015
8	Thymidine KinaseIBA 06/2013 - 11/2002
7	Busulfan (Busulfex)FDA Link 01/2022 - 01/2009
6	Interleukin-1 (Interleukin 1)IBA 04/2021 - 01/2018
6	Biological ProductsIBA 11/2020 - 04/2012
5	fludarabineIBA 01/2022 - 01/2002
5	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2022 - 12/2009
5	Chimeric Antigen ReceptorsIBA 01/2022 - 01/2018
5	VaccinesIBA 01/2022 - 02/2009
5	SteroidsIBA 10/2021 - 11/2004
5	Monoclonal AntibodiesIBA 01/2021 - 01/2018
4	AutoantibodiesIBA 01/2022 - 10/2020
4	TroponinIBA 01/2022 - 01/2018
4	Neoplasm Antigens (Tumor Antigens)IBA 01/2022 - 10/2007
4	Sirolimus (Rapamycin)FDA Link 01/2022 - 01/2011
4	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2022 - 05/2012
4	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 09/2019
4	AntibodiesIBA 11/2021 - 05/2010
4	Oxygen (Dioxygen)IBA 10/2021 - 04/2020
4	Adenosine DeaminaseIBA 01/2021 - 01/2009
4	Complement System Proteins (Complement)IBA 11/2020 - 01/2020
4	Hemoglobins (Hemoglobin)IBA 01/2019 - 11/2005
3	Blood Glucose (Blood Sugar)IBA 01/2022 - 10/2021
3	Immunoglobulin G (IgG)IBA 01/2022 - 10/2020
3	defibrotideIBA 01/2022 - 01/2018
3	HLA-A Antigens (HLA-A)IBA 01/2022 - 04/2017
3	tocilizumab (atlizumab)FDA Link 11/2021 - 01/2018
3	IronIBA 10/2021 - 06/2012
3	Proteins (Proteins, Gene)FDA Link 10/2021 - 10/2007
3	fibrin fragment D (D-dimer)IBA 10/2021 - 04/2020
3	Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link 01/2021 - 01/2018
3	Mycophenolic Acid (Cellcept)FDA LinkGeneric 12/2020 - 03/2016
3	Calcineurin InhibitorsIBA 12/2020 - 03/2016
3	AnthracyclinesIBA 05/2020 - 01/2018
3	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2020 - 08/2015
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2020 - 11/2004

Therapy/Procedure

78	Hematopoietic Stem Cell Transplantation 10/2022 - 01/2006
74	Transplantation 10/2022 - 01/2002
60	Stem Cell Transplantation 01/2022 - 11/2002
42	Therapeutics 02/2022 - 06/2005
37	Cell Transplantation 01/2022 - 11/2002
25	Drug Therapy (Chemotherapy) 11/2021 - 03/2008
19	Haploidentical Transplantation 01/2022 - 07/2009
15	Immunotherapy 01/2022 - 11/2004
12	Homologous Transplantation 01/2020 - 01/2002
5	Bone Marrow Transplantation (Transplantation, Bone Marrow) 01/2021 - 09/2014
5	Autologous Transplantation 08/2020 - 05/2010
4	Radiotherapy 04/2014 - 06/2009
3	Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell Transplantation) 10/2022 - 01/2017
3	Noninvasive Ventilation 01/2022 - 06/2020